Latest News about ATAI
Recent news which mentions ATAI
Psilera's DMT-Derived Drug Sees Positive Results in Pre-Clinical Study
December 09, 2021
From Benzinga
National Institute on Drug Abuse Will Test Ibogaine For Addiction Treatment As Drug Deaths Crest 100,000
December 08, 2021
From Benzinga
This Company Is Making Synthetic Psychedelics With a Goal To Combat Mental Illness
December 08, 2021
From Benzinga
New York's Horizons Psychedelic Conference Highlights Big Donations In The Growing Industry
December 07, 2021
From Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 30, 2021
November 30, 2021
From Benzinga
Peter Thiel-Backed Psychedelic Start-Up, ATAI Life Sciences, Increases Stake In Compass Pathways
November 29, 2021
From Benzinga
70 Biggest Movers From Yesterday
November 16, 2021
From Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 11, 2021
November 11, 2021
From Benzinga
This Psychedelics Stock Was Up More Than 20% Last Week, Outperforming Tesla, Nvidia and GameStop
November 02, 2021
From Benzinga
These 4 Psychedelic Biotech Stocks Are Leading the Pack
October 26, 2021
From Motley Fool
Psyched: The 50 Publicly-listed Psychedelics Companies, Atai's New Subsidiary, PharmaTher Gets New Orphan Drug Designation
October 18, 2021
From Benzinga
From Benzinga
From MarketWatch
What Is Precision Psychiatry? Biotech Company Leverages New Approach To Mental Health Disorders
October 11, 2021
Tickers
ATAI
From Benzinga
Biotech Company Pasithea Therapeutics Teams Up With Evotec to Aid Mental Health Drug Discovery
October 11, 2021
From Benzinga
The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal
October 06, 2021
From Benzinga
The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout
October 05, 2021
From Benzinga
Psyched: Delic Buys 10 Ketamine Clinics For $10M, Atai Launches Ibogaine Human Trials, Small Pharma Concludes Phase 1 DMT Study
September 27, 2021
From Benzinga
Can Ibogaine Treat Opioid Addiction? Nasdaq-Listed Atai Is Launching A Trial To Find Out
September 21, 2021
Tickers
ATAI
From Benzinga
Psyched: First Active Psychedelics ETF Hits NYSE, Compass Dives Into Novel Molecules, Atai Subsidiary Launches Phase 2a Trial
September 20, 2021
From Benzinga
Can Ketamine For Depression Be Improved? New Study Will Looks Into Ketamine Analog Arketamine
September 14, 2021
From Benzinga
Psyched: CaamTech Raises $22M, Mydecine To Launch Smoking Cessation Trial, Michigan Bill Could Decriminalize Psychedelics
September 13, 2021
From Benzinga
Psychedelic Medicine's Top CEOs: Who's Running The Biggest Companies In This Booming Industry?
September 09, 2021
From Benzinga
What 10 Analyst Ratings Have To Say About ATAI Life Sciences
September 01, 2021
Tickers
ATAI
From Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 1, 2021
September 01, 2021
From Benzinga
21 Stocks Moving in Wednesday's Pre-Market Session
September 01, 2021
From Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.
Never miss important news. Subscribe to our newsletter.
Register for free
Information
Copyright 2024. BUSINESS INSURANCE HOLDINGS
